The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Screening for prostate cancer
Open accessAbstract
BACKGROUND: Any form of screening aims to reduce disease-specific and overall mortality, and to improve a person's future quality of life. Screening for prostate cancer has generated considerable debate within the medical and broader community, as demonstrated by the varying recommendations made by medical organizations and governed by national policies. To better inform individual patient decision-making and health policy decisions, we need to consider the entire body of data from randomised controlled trials (RCTs) on prostate cancer screening summarised in a systematic review. In 2006, our Cochrane review identified insufficient evidence to either support or refute the use of routine mass, selective, or opportunistic screening for prostate cancer. An update of the review in 2010 included three additional trials. Meta-analysis of the five studies included in the 2010 review concluded that screening did not significantly reduce prostate cancer-specific mortality. In the past two years, several updates to studies included in the 2010 review have been published thereby providing the rationale for this update of the 2010 systematic review. OBJECTIVES: To determine whether screening for prostate cancer reduces prostate cancer-specific mortality or all-cause mortality and to assess its impact on quality of life and adverse events. SEARCH METHODS: An updated search of electronic databases (PROSTATE register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CANCERLIT, and the NHS EED) was performed, in addition to handsearching of specific journals and bibliographies, in an effort to identify both published and unpublished trials. SELECTION CRITERIA: All RCTs of screening versus no screening for prostate cancer were eligible for inclusion in this review. DATA COLLECTION AND ANALYSIS: The original search (2006) identified 99 potentially relevant articles that were selected for full-text review. From these citations, two RCTs were identified as meeting the inclusion criteria. The search for the 2010 version of the review identified a further 106 potentially relevant articles, from which three new RCTs were included in the review. A total of 31 articles were retrieved for full-text examination based on the updated search in 2012. Updated data on three studies were included in this review. Data from the trials were independently extracted by two authors. MAIN RESULTS: Five RCTs with a total of 341,342 participants were included in this review. All involved prostate-specific antigen (PSA) testing, with or without digital rectal examination (DRE), though the interval and threshold for further evaluation varied across trials. The age of participants ranged from 45 to 80 years and duration of follow-up from 7 to 20 years. Our meta-analysis of the five included studies indicated no statistically significant difference in prostate cancer-specific mortality between men randomised to the screening and control groups (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.86 to 1.17). The methodological quality of three of the studies was assessed as posing a high risk of bias. The European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial were assessed as posing a low risk of bias, but provided contradicting results. The ERSPC study reported a significant reduction in prostate cancer-specific mortality (RR 0.84, 95% CI 0.73 to 0.95), whilst the PLCO study concluded no significant benefit (RR 1.15, 95% CI 0.86 to 1.54). The ERSPC was the only study of the five included in this review that reported a significant reduction in prostate cancer-specific mortality, in a pre-specified subgroup of men aged 55 to 69 years of age. Sensitivity analysis for overall risk of bias indicated no significant difference in prostate cancer-specific mortality when referring to the meta analysis of only the ERSPC and PLCO trial data (RR 0.96, 95% CI 0.70 to 1.30). Subgroup analyses indicated that prostate cancer-specific mortality was not affected by the age at which participants were screened. Meta-analysis of four studies investigating all-cause mortality did not determine any significant differences between men randomised to screening or control (RR 1.00, 95% CI 0.96 to 1.03). A diagnosis of prostate cancer was significantly greater in men randomised to screening compared to those randomised to control (RR 1.30, 95% CI 1.02 to 1.65). Localised prostate cancer was more commonly diagnosed in men randomised to screening (RR 1.79, 95% CI 1.19 to 2.70), whilst the proportion of men diagnosed with advanced prostate cancer was significantly lower in the screening group compared to the men serving as controls (RR 0.80, 95% CI 0.73 to 0.87). Screening resulted in a range of harms that can be considered minor to major in severity and duration. Common minor harms from screening include bleeding, bruising and short-term anxiety. Common major
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,178
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Principles and Practice of Screening for Disease.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-5-1085_2 · Cited by 3,066
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Cited by
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Crosby, D., Bhatia, S., Brindle, K. M., Coussens, L. M., Dive, C., Emberton, M., Esener, S., Fitzgerald, R. C., Gambhir, S. S., Kuhn, P., et al. (2022) · Science · doi:10.1126/science.aay9040 · Cited by 1,379
Prostate-Cancer Mortality at 11 Years of Follow-up
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113135 · Cited by 1,245
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
Ilic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., Agoritsas, T., & Dahm, P. (2018) · BMJ · doi:10.1136/bmj.k3519 · Cited by 641
Self-citationDrost, F.-J. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., & Schoots, I. G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012663.pub2 · Cited by 640
Patel, M. R., Calhoon, J. H., Dehmer, G. J., Grantham, J. A., Maddox, T. M., Maron, D. J., & Smith, P. K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.001 · Cited by 620
Towards clinical utility of polygenic risk scores
Lambert, S. A., Abraham, G., & Inouye, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz187 · Cited by 575
Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
Chou, R., Croswell, J. M., Dana, T., Bougatsos, C., Blazina, I., Fu, R., Gleitsmann, K., Koenig, H. C., Lam, C., Maltz, A., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00375 · Cited by 573
Why screening tests to predict injury do not work—and probably never will…: a critical review
Bahr, R. (2016) · British Journal of Sports Medicine · doi:10.1136/bjsports-2016-096256 · Cited by 562
Brown, K. F., Rumgay, H., Dunlop, C., Ryan, M., Quartly, F., Cox, A., Deas, A., Elliss-Brookes, L., Gavin, A., Hounsome, L., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0029-6 · Cited by 557
Eichler, K., Hempel, S., Wilby, J., Myers, L., Bachmann, L. M., & Kleijnen, J. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00957-2 · Cited by 518
Pokorny, M. R., de Rooij, M., Duncan, E., Schröder, F. H., Parkinson, R., Barentsz, J. O., & Thompson, L. C. (2014) · European Urology · doi:10.1016/j.eururo.2014.03.002 · Cited by 503
Prevention and early detection of prostate cancer
Cuzick, J., Thorat, M. A., Andriole, G., Brawley, O. W., Brown, P. H., Culig, Z., Eeles, R. A., Ford, L. G., Hamdy, F. C., Holmberg, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70211-6 · Cited by 495
Self-citationPatel, M. R., Calhoon, J. H., Dehmer, G. J., Grantham, J. A., Maddox, T. M., Maron, D. J., & Smith, P. K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.034 · Cited by 493
Light In and Sound Out: Emerging Translational Strategies for Photoacoustic Imaging
Zackrisson, S., van de Ven, S. M. W. Y., & Gambhir, S. S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2387 · Cited by 480
American Cancer Society prostate cancer survivorship care guidelines
Skolarus, T. A., Wolf, A. M. D., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., Salner, A. L., Zelefsky, M. J., Aragon‐Ching, J. B., Slovin, S. F., et al. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21234 · Cited by 398
Metabolic Fingerprinting As A Diagnostic Tool
Ellis, D. I., Dunn, W. B., Griffin, J. L., Allwood, J. W., & Goodacre, R. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.9.1243 · Cited by 396
Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only
Hugosson, J., Månsson, M., Wallström, J., Axcrona, U., Carlsson, S. V., Egevad, L., Geterud, K., Khatami, A., Kohestani, K., Pihl, C.-G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209454 · Cited by 381
Screening for Prostate Cancer With the Prostate-Specific Antigen Test: A Review of Current Evidence
Hayes, J. H., & Barry, M. J. (2014) · JAMA · doi:10.1001/jama.2014.2085 · Cited by 361
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials
Djulbegovic, M., Beyth, R. J., Neuberger, M. M., Stoffs, T. L., Vieweg, J., Djulbegovic, B., & Dahm, P. (2010) · BMJ · doi:10.1136/bmj.c4543 · Cited by 337
Self-citationRisk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp122 · Cited by 336
MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges
Lan, H., Lu, H., Wang, X., & Jin, H. (2015) · BioMed Research International · doi:10.1155/2015/125094 · Cited by 330
Karnes, R. J., Bergstralh, E. J., Davicioni, E., Ghadessi, M., Buerki, C., Mitra, A. P., Crisan, A., Erho, N., Vergara, I. A., Lam, L. L., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.06.017 · Cited by 325
Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer
Albertsen, P. C., Moore, D. F., Shih, W., Lin, Y., Li, H., & Lu-Yao, G. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2330 · Cited by 312
Lin, K., Lipsitz, R., Miller, T., & Janakiraman, S. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-3-200808050-00009 · Cited by 310
Screening for Cancer in Low- and Middle-Income Countries
Sankaranarayanan, R. (2014) · Annals of Global Health · doi:10.1016/j.aogh.2014.09.014 · Cited by 296
Impact of Patient Navigation on Timely Cancer Care: The Patient Navigation Research Program
Freund, K. M., Battaglia, T. A., Calhoun, E., Darnell, J. S., Dudley, D. J., Fiscella, K., Hare, M. L., LaVerda, N., Lee, J.-H., Levine, P., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju115 · Cited by 303
The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer
Loeb, S., Sanda, M. G., Broyles, D. L., Shin, S. S., Bangma, C. H., Wei, J. T., Partin, A. W., Klee, G. G., Slawin, K. M., Marks, L. S., et al. (2015) · Journal of Urology · doi:10.1016/j.juro.2014.10.121 · Cited by 300
Enhancing the Health-Promoting Effects of Tomato Fruit for Biofortified Food
Raiola, A., Rigano, M. M., Calafiore, R., Frusciante, L., & Barone, A. (2014) · Mediators of Inflammation · doi:10.1155/2014/139873 · Cited by 293
General health checks in adults for reducing morbidity and mortality from disease
Krogsbøll, L. T., Jørgensen, K. J., Grønhøj Larsen, C., & Gøtzsche, P. C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009009.pub2 · Cited by 289
Padhani, A. R., Weinreb, J., Rosenkrantz, A. B., Villeirs, G., Turkbey, B., & Barentsz, J. (2019) · European Urology · doi:10.1016/j.eururo.2018.05.035 · Cited by 288
Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study
Collin, S. M., Martin, R. M., Metcalfe, C., Gunnell, D., Albertsen, P. C., Neal, D., Hamdy, F., Stephens, P., Lane, J. A., Moore, R., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70104-9 · Cited by 272
Naji, L., Randhawa, H., Sohani, Z., Dennis, B., Lautenbach, D., Kavanagh, O., Bawor, M., Banfield, L., & Profetto, J. (2018) · The Annals of Family Medicine · doi:10.1370/afm.2205 · Cited by 271
on behalf of the Transatlantic Prostate Group, Cuzick, J., Stone, S., Fisher, G., Yang, Z. H., North, B. V., Berney, D. M., Beltran, L., Greenberg, D., Møller, H., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.223 · Cited by 155
Reconsidering the age thresholds for type II diabetes screening in the U.S
Chung, S., Azar, K. M. J., Baek, M., Lauderdale, D. S., & Palaniappan, L. P. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.05.012 · Cited by 36
Patel, M. R., Calhoon, J. H., Dehmer, G. J., Grantham, J. A., Maddox, T. M., Maron, D. J., & Smith, P. K. (2018) · Journal of Nuclear Cardiology · doi:10.1007/s12350-018-1292-x · Cited by 11
Metadata
- Authors
- Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2013-01-31
- Volume
- 2013
- Issue
- 1
- Pages
- CD004720-CD004720
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2144298794
- Cited by
- 1,150
- References
- 123
- FWCI
- 115.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.